Page last updated: 2024-08-23

staurosporine and Abnormalities, Autosome

staurosporine has been researched along with Abnormalities, Autosome in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
George, TI; Gotlib, J; Reiter, A1
Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ1
Cavelier, C; Demur, C; Didier, C; Ducommun, B; Manenti, S; Mansat-De Mas, V; Prade, N; Recher, C1
Azuma, A; Chubb, S; Guo, Y; Hittelman, W; Huang, P; Jiang, Y; Li, Y; Liu, X; Matsuda, A; Plunkett, W1
Guo, L; Liu, X; Nishikawa, K; Plunkett, W1

Reviews

1 review(s) available for staurosporine and Abnormalities, Autosome

ArticleYear
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
    Blood, 2020, 04-16, Volume: 135, Issue:16

    Topics: Animals; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Mastocytosis, Systemic; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines

2020

Other Studies

4 other study(ies) available for staurosporine and Abnormalities, Autosome

ArticleYear
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult

2016
Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.
    Cancer research, 2009, Nov-15, Volume: 69, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Child; Chromosome Aberrations; DNA Damage; Flow Cytometry; Fluorescent Antibody Technique; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein Kinases; RNA Interference; Signal Transduction; Staurosporine

2009
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
    Cancer research, 2005, Aug-01, Volume: 65, Issue:15

    Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Chromosome Aberrations; Cytarabine; DNA Damage; Drug Interactions; G2 Phase; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Mitosis; Protein Kinases; Signal Transduction; Staurosporine

2005
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:5

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Clinical Trials as Topic; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; G2 Phase; Histones; Humans; Leukemia, Myeloid, Acute; Phenanthrenes; Phenanthridines; Phosphorylation; Staurosporine; Topoisomerase II Inhibitors

2007